1. Home >
  2. M&A >
  3. Merger >
  4. United States >
  5. Massachusetts >
  6. Ocugen Acquires Histogenics

M&A Deal Summary

Ocugen Acquires Histogenics

On September 30, 2019, Ocugen acquired life science company Histogenics

Acquisition Highlights
  • This is Ocugen’s 1st transaction in the Life Science sector.
  • This is Ocugen’s 1st transaction in the United States.
  • This is Ocugen’s 1st transaction in Massachusetts.

M&A Deal Summary
Date 2019-09-30
Target Histogenics
Sector Life Science
Buyer(s) Ocugen
Deal Type Merger
Advisor(s) Canaccord Genuity (Financial)
Gunderson Dettmer (Legal)

Target

Histogenics

Waltham, Massachusetts, United States
Histogenics is a regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. Histogenics was founded in 2000 and is based in Waltham, Massachusetts.

Search 214,600 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Ocugen

Malvern, Pennsylvania, United States
Category Company
Founded 2013
Sector Life Science
Employees95
Revenue 4M USD (2024)
DESCRIPTION

Ocugen is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. Ocugen was founded in 2013 and is based in Malvern, Pennsylvania.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Merger M&A Deals 1 of 1
State: Massachusetts M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2019 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal